Sequenta

About:

Sequenta is engaged in the discovery and development of clinical diagnostics based on a platform for understanding immune system status.

Website: http://www.sequenta.com/

Twitter/X: SequentaInc

Top Investors: Foresite Capital, Index Ventures, Mohr Davidow Ventures, Celgene, Farzad Nazem

Description:

Sequenta is a venture funded biotech company dedicated to the discovery and development of clinical diagnostics based on a revolutionary new platform for understanding immune system status. A profound revolution in the cost of DNA sequencing has enabled the company to develop brand new approaches to measuring the most variable part of the human genome: the immune cell receptor genes. The incredible diversity created by these genes are at the heart of a large number of conditions critical to human health and disease allowing the company to be in a position to inform a large number of clinical decisions using a single powerful assay. The company was founded in 2008 by entrepreneurs who previously founded ParaAllele BioScience, a successful startup company sold to Affymetrix in 2005.

Total Funding Amount:

$43.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2008-01-01

Contact Email:

tom.willis(AT)mlcdx.com

Founders:

Malek Faham, Tom Willis

Number of Employees:

51-100

Last Funding Date:

2014-10-20

IPO Status:

Private

Industries:

© 2025 bioDAO.ai